One future approach to treatment of these tumors may rely on concurrent pharmacological depletion of tumor MGMT with O6-benzylguanine ( 6-BG ) and protection of sensitive tissues , such as hematopoietic stem and progenitor cells , using genetic modification with 6-BG -resistant MGMT mutants .